Last reviewed · How we verify
NCT07291947
PULSAR Combined With Immunotherapy and Chemotherapy
Phase 1, PHASE2 trial testing Iparomlimab and Tuvonralimab Injection (QL1706) in Cholangiocarcinoma in 60 participants. Currently enrolling.
10 September 2026
Quick facts
| Lead sponsor | Wang Xin |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 4 November 2025 |
| Primary completion | 10 September 2026 |
| Estimated completion | 10 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Iparomlimab and Tuvonralimab Injection (QL1706)
- PULSAR
Conditions studied
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Sponsor
Wang Xin — full company profile →
Who can join
Adults 18 to 75, any sex, with Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the efficacy and safety of PULSAR in combination with dual immune checkpoint inhibitors (PD-1 monoclonal antibody + CTLA-4 monoclonal antibody) and GC chemotherapy in patients with locally advanced or metastatic cholangiocarcinoma. The secondary objective of this study is to investigate the immunological impact of PULSAR combined with dual immune therapy (PD-1 monoclonal antibody + CTLA-4 monoclonal antibody) on the tumor microenvironment and systemic immune responses in cholangiocarcinoma patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07291947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Iparomlimab and Tuvonralimab Injection (QL1706)
Trials testing the same drug.
- NCT07327788 — QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT · Phase 2 · recruiting
- NCT07128251 — A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlima · Phase 2 · not yet recruiting
- NCT07131501 — A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL17 · Phase 2 · not yet recruiting
Other recruiting trials for Cholangiocarcinoma
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
- NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting
- NCT06503146 — 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection · Phase 2 · recruiting
Other Wang Xin trials
Trials by the same sponsor.
- NCT07463248 — PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line · Phase 2 · not yet recruiting
- NCT06334367 — Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT · Phase 2 · unknown
- NCT05920668 — Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07291947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wang Xin
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07291947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing